
For research use only. We do not supply to patients.
For pharmaceutical-grade products or other inquiries, please contact our experts.
This review discusses glucocorticoid replacement in hypoadrenalism. Mortality gap persists between treated patients and the general population, possibly due to loss of circadian/ultradian rhythm. Prednisolone and dual-release hydrocortisone (Plenadren) provide smoother profiles. Very low-dose prednisolone (2–4 mg daily) may offer better cardiometabolic outcomes, but evidence is limited.
Fig. 1 Model of glucocorticoid sensitivity in peripheral tissue as it fluctuates during the day. (Choudhury S, et al., 2021)
References
In primary human endometrial stromal fibroblasts (hESFs), prednisolone treatment reduced cytokine expression (IL6, IL11, IL18, LIF, LIFR) but did not affect classic decidualization markers (PRL, IGFBP1). Proteomics revealed prednisolone altered decidualized hESF protein production, enriching proteins associated with acetylation and mitochondria. Conditioned media from prednisolone-treated decidualized hESFs enhanced trophoblast outgrowth and PLCG1 expression while reducing PGF. Prednisolone during the menstrual cycle and first trimester may alter decidual interactions with trophoblasts.
Fig. 2 Analysis of differently regulated decidualized human endometrial stromal fibroblast (hESF) proteins following in vitro decidualization in the presence of prednisolone. (Grbac E, et al., 2021)
References
Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed
All our products are chemicals for research purposes only. We do not supply for human or veterinary applications.
Privacy Policy | Cookie Policy Copyright © Protheragen. All Rights Reserved.
